What we found
These came out of reading 51 clinics' own pages, and they are why this site exists rather than a directory. Each carries its source and the date we checked it. 20 of the 22 are serious enough that we would want to know before paying.
22 findings
Third-party record
bmiMD displays a 4.9 rating; its own Trustpilot profile reads 4.4
bmiMD's product pages display “4.9 Avg. Rating, 1,000+ Reviews”. Its own Trustpilot profile (claimed, on the bmimd.com domain our link resolves to) reads 4.4 across 872 reviews. Both read live 2026-10-02. 4.4 across 872 reviews is a strong independent record, better than most clinics here; the gap is that the number on bmiMD's own page is higher and rounder than the one anyone can verify.
Our link's price is not the public price
bmiMD shows a different price on our link than in public
Our affiliate path showed $99 (per-month) while its public page showed $119 (per-month). We score and publish the PUBLIC figure, and this clinic is held out of any promoted slot for it. The price we show has to be the price a stranger sees.
Our link's price is not the public price
CoreAge Rx shows a different price on our link than in public
Our affiliate path showed $79 (per-month) while its public page showed $99 (per-month). We score and publish the PUBLIC figure, and this clinic is held out of any promoted slot for it. The price we show has to be the price a stranger sees.
SourceChecked 2026-09-16Clinic: coreage-rx-glp-1
Third-party record
CoreAge Rx's Trustpilot rating is suspended by Trustpilot
Trustpilot has SUSPENDED this company's rating itself. Banner verbatim: “This company's rating is unavailable due to a breach of our guidelines”, plus “We've removed a number of fake reviews for this company.” Domain confirmed as coreagerx.com before the figure was used.
SourceChecked 2026-08-31Clinic: coreage-rx-glp-1
Two storefronts, one company
Embody and SnagRx are the same company
Both publish the same legal entity, Modern Metabolic Medicine, Inc., and neither site says they are related. They appear separately in this ranking, so they can look like two independent options when they are one. Compare them knowing that.
Our link's price is not the public price
Embody shows a different price on our link than in public
Our affiliate path showed $69 (per-month) while its public page showed $79 (per-month). We score and publish the PUBLIC figure, and this clinic is held out of any promoted slot for it. The price we show has to be the price a stranger sees.
Regulatory action
FDA warning letter naming directmeds.com, Inc. dba DirectMeds
Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth). Letter 716822, dated 2025-09-09. FDA states it "reviewed your website content at the internet address https://directmeds.com in August 2025", the same domain we record for this clinic, and found it offers compounded drug products including semaglutide and tirzepatide. FDA quotes the claim that “Compounded semaglutide contains the same active ingredient as branded semaglutide” and alleges the claims are false or misleading under sections 502(a) and 502(bb) of the FD&C Act [21 U.S.C. §§ 352(a), 352(bb)], rendering the products misbranded, and that introducing them into interstate commerce violates section 301(a) [21 U.S.C. § 331(a)]. The letter is addressed to the company at 14572 S 790 W #A100, Bluffdale, UT 84065. This is an allegation by FDA, not an adjudicated finding, and Direct Meds has not been shown to have been found liable by any court. No closeout letter has been posted.
SourceClinic: direct-meds
Regulatory action
FDA warning letter naming Eden Health International Inc. dba Eden
False & Misleading Claims/Misbranded (Telehealth). Letter 728279, dated 2026-06-08. FDA states it reviewed tryeden.com (FEI 3044020039) in March 2026. Compounded semaglutide and tirzepatide were pictured with labels identifying "Eden", suggesting Eden compounds them when it does not, and the site called its suppliers "FDA-licensed 503(a) outsourcing facilities", a designation FDA does not grant. Misbranded under FDCA 502(a) and 502(bb). Recipient address: 110 16th St Ste 1431, Denver, CO 80202. No closeout letter has been posted.
SourceClinic: eden-health
Regulatory action
FDA warning letter naming FitRX, LLC dba Zealthy
Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth). Letter 716501, dated 2025-09-09. FDA states it reviewed getzealthy.com in August 2025 and cites on-site claims, for example "Semaglutide is the active ingredient in Wegovy and Ozempic", for implying the compounded semaglutide sold is the same as the FDA-approved product. FDA states compounded drugs are not FDA-approved, making the claims false or misleading and the products misbranded under FDCA sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]. The recipient, FitRX, LLC dba Zealthy (30 Irving Pl, New York, NY), is the operating company on our review. This is an allegation by FDA, not an adjudicated finding. No closeout letter has been posted.
Regulatory action
FDA warning letter naming Ivim Services LLC dba Ivim
False & Misleading Claims/Misbranded (Telehealth). Letter 721816, dated 2026-02-20. FDA states the compounded semaglutide and tirzepatide products displayed on Ivim's website identify "Ivim" on the pictured label, "suggesting Ivim is the compounder of those drugs when in fact it is not". The recipient, Ivim Services LLC (4200 Regent Street, Suite 200, Columbus, OH), is the entity named in ivimhealth.com's Terms and on our review. This is an allegation by FDA, not an adjudicated finding. No closeout letter has been posted.
SourceClinic: ivim-health
Regulatory action
FDA warning letter naming Lean Rx, Inc. dba SkinnyRx
False & Misleading Claims/Misbranded (Telehealth). Letter 717989, dated 2026-02-20. FDA states it "reviewed your website content at the internet address https://skinnyrx.com, in December 2025". The same domain we record for this clinic. Two distinct allegations. First, labelling: the compounded semaglutide and tirzepatide products shown on the site “identify ‘SkinnyRx’ on the pictured label, suggesting SkinnyRx is the compounder of those drugs when in fact it is not.” Second, claims: FDA quotes “from the same family as GLP-1 treatments like Mounjaro® and Zepbound®”, “Get access to the same active ingredient as name-brand GLP-1 medications” and “It contains the same active ingredient as FDA-approved medications”, alleging they imply FDA approval or evaluation the compounded products do not have. FDA cites sections 502(a) and 502(bb) of the FD&C Act [21 U.S.C. §§ 352(a), 352(bb)] and section 301(a) [21 U.S.C. § 331(a)]. This is an allegation by FDA, not an adjudicated finding, and SkinnyRx has not been shown to have been found liable by any court. No closeout letter has been posted.
Regulatory action
FDA warning letter naming Lovely Meds, Inc.
False & Misleading Claims (compounded semaglutide/tirzepatide). Letter 716829, dated 2025-09-09. FDA alleges false claims about compounded semaglutide and tirzepatide. The letter was issued over lovelymeds.com, a DIFFERENT property of the same entity. Not over tryageless.com. Lovely Meds, Inc. is the entity named in the footer of the Ageless GLP-1 page our link lands on, which is why it is recorded here. This is an allegation by FDA against the OPERATOR, not an adjudicated finding, and not a letter against this brand's own page. No closeout letter has been posted.
Regulatory action
FDA warning letter naming Maximus Health, Inc. dba Maximus
False & Misleading Claims/Misbranded (Telehealth). Letter 730095, dated 2026-06-08. FDA states that "violations were identified and documented during a review of Maximus' website, https://www.maximustribe.com, FDA Establishment Identifier (FEI) 3032037948, in May 2026". The same domain we record for this clinic. FDA quotes representations including “Clinically studied ingredients”, “Proven to lose weight effectively” and products sourced from “FDA approved pharmacies”, and alleges they misrepresent unapproved compounded drugs as FDA-evaluated or FDA-authorised. FDA cites sections 502(a) and 502(bb) of the FD&C Act [21 U.S.C. §§ 352(a), 352(bb)] and section 301(a) [21 U.S.C. § 331(a)]. Part of the wave of 30 warning letters FDA announced to telehealth companies over compounded GLP-1 marketing. This is an allegation by FDA, not an adjudicated finding, and Maximus has not been shown to have been found liable by any court. No closeout letter has been posted.
Regulatory action
FDA warning letter naming Remedy Meds
Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth). Letter 716830, dated 2025-09-09. FDA states it reviewed remedymeds.com in August 2025 and that the site's claims "Semaglutide (Compounded) Same active ingredient as Ozempic and Wegovy" and "Tirzepatide (Compounded) Same active ingredient as Mounjaro and Zepbound" imply the compounded products are the same as FDA-approved ones, making them misbranded under FDCA 502(a) and 502(bb). Recipient address: 480 Morris Ave, Summit, NJ 07901. This is an allegation by FDA, not an adjudicated finding. No closeout letter has been posted.
SourceClinic: remedy-meds
Regulatory action
FDA warning letter naming Sprout Health Partners LLC dba Sprout Health
Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth). Letter 715879, dated 2025-09-09. FDA states it "reviewed your website content at the internet address https://joinsprouthealth.com in August 2025", the same domain our link lands on, and observed that the site offers compounded drug products including semaglutide and tirzepatide. FDA quotes the site's claim that “GLP-1 medications are FDA-approved and backed by extensive clinical research” and alleges that compounded drug products are not FDA-approved, so the claim implies an approval the products do not have. FDA cites sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. §§ 352(a), 352(bb)] and sections 301(a) and 301(c) [21 U.S.C. §§ 331(a), 331(c)]. This is an allegation by FDA, not an adjudicated finding, and Sprout has not been shown to have been found liable by any court. No closeout letter has been posted.
SourceClinic: sprout-health
Regulatory action
FDA warning letter naming Strut Health, LLC dba Strut
False & Misleading Claims/Misbranded (Telehealth). Letter 721448, dated 2026-02-20. FDA states it reviewed struthealth.com in December 2025 and observed that the website "offers compounded drug products, including semaglutide and tirzepatide drug products". FDA alleges the website's "false or misleading claims concerning compounded semaglutide and tirzepatide products" render those products misbranded under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. §§ 352(a), 352(bb)], and that introducing them into interstate commerce violates section 301(a) [21 U.S.C. § 331(a)]. This is an allegation by FDA, not an adjudicated finding, and Strut has not been shown to have been found liable by any court. No closeout letter has been posted.
SourceClinic: strut-health
Third-party record
Lttl displays a 4.5 rating; its own Trustpilot profile reads 4.2
Lttl's homepage shows “4.5★ from 125,000+ Members” and its product pages “Excellent TrustPilot 125,000+ happy customers”. Its own Trustpilot profile (claimed, paid subscription, domain lttl.com, 21600 Oxnard St, Woodland Hills) read 4.2 across 12 reviews on 2026-10-27: 92% five-star, 8% one-star. The newest review (16 October 2026) describes a week's wait for medication with no tracking number. The oldest review is from July 2026. Both read live 2026-10-27.
Our link's price is not the public price
Sprout Health shows a different price on our link than in public
Our affiliate path showed $110 (per-month) while its public page showed $299 (per-month). We score and publish the PUBLIC figure, and this clinic is held out of any promoted slot for it. The price we show has to be the price a stranger sees.
SourceChecked 2026-09-17Clinic: sprout-health
The same review, two different prices
Sprout Health shows the same customer review with two different prices
A review attributed to Joan (“Verified Customer”, dated May 17 2026 on the affiliate page) appears word for word on both surfaces, with one figure changed. On the page our affiliate link lands on it reads “…I pay a flat fee of $149 each month…”; on its public page the same review reads “…I pay a flat fee of $299. each month…”. Same name, same date, same wording including the same typos. At least one version is not what the customer wrote.
SourceChecked 2026-09-17Clinic: sprout-health
Third-party record
Willow displays a 4.9 rating; its own Trustpilot profile reads 3.9
Willow's product pages display “4.9/5 (2200 + 5 star reviews)”. Its own Trustpilot profile (claimed December 2024, with a paid Trustpilot subscription) reads 3.9 across 357 reviews, 117 of them in the last 12 months, with a split distribution rather than an average one: 58% five-star against 31% one-star. Both figures re-read live 2026-09-30. Willow does not attribute the 4.9 to Trustpilot, so this is not a case of showing a platform's branded score after the platform withdrew it. The profile is live, claimed and rated. But the review-volume claim is more than six times the independent count and the rating is a full point higher, and Willow replies to its negative reviews, so it reads them.
The ongoing rate is not published
SkinnyRx publishes a first-month price and not the one after it
Read the whole product page through a browser (including the subscription, refill and refund sections) and the month-two rate appears nowhere. The only figure published is "$99 first month", under a "while supplies last" banner. So what you pay from month two is unknown before you sign up.
Checked 2026-09-14Clinic: skinnyrx
Third-party record
Strut Health's 3.5 rating rests on old reviews
Only 43 of 777 reviews (6%) are from the last 12 months, so the score describes years-old experience rather than current service.
SourceChecked 2026-08-30Clinic: strut-health
How these are produced
Every finding here comes from a fact we can point to, never from opinion: the legal entity each brand publishes, FDA warning letters, third-party review sites, and the comparison between the price on our affiliate link and the price on the clinic's public page. A finding that cannot be traced to one of those sources does not appear, and every finding we record is shown somewhere on the site. Editorial policy.
An FDA warning letter is an allegation by the agency, not a court ruling, and we say so on each one. Where litigation is contested, we say that too.